Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117


Metformin inhibits goitrogenous effects of type 2 diabetes.

Ittermann T, Markus MR, Schipf S, Derwahl M, Meisinger C, Völzke H.

Eur J Endocrinol. 2013 May 17;169(1):9-15. doi: 10.1530/EJE-13-0101. Print 2013 Jul.


Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.


Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome.

Blanc E, Ponce C, Brodschi D, Nepote A, Barreto A, Schnitman M, Fossati P, Salgado P, Cejas C, Faingold C, Musso C, Brenta G.

Metab Syndr Relat Disord. 2015 Jun;13(5):221-6. doi: 10.1089/met.2014.0158. Epub 2015 Mar 19.


Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study.

Bruderer SG, Bodmer M, Jick SS, Meier CR.

Ann Rheum Dis. 2015 Sep;74(9):1651-8. doi: 10.1136/annrheumdis-2014-205337. Epub 2014 Apr 12.


The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.

Smolen HJ, Murphy DR, Gahn JC, Yu X, Curtis BH.

J Manag Care Spec Pharm. 2014 Sep;20(9):968-84.


Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study.

Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P.

Cardiovasc Diabetol. 2010 Apr 21;9:15. doi: 10.1186/1475-2840-9-15.


Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.

Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL.

J Clin Endocrinol Metab. 2013 Feb;98(2):668-77. doi: 10.1210/jc.2012-3042. Epub 2013 Jan 31.


Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.

Tseng CH.

Eur J Cancer. 2014 Nov;50(16):2831-7. doi: 10.1016/j.ejca.2014.08.007. Epub 2014 Sep 5.


Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study.

Wahlqvist ML, Lee MS, Chuang SY, Hsu CC, Tsai HN, Yu SH, Chang HY.

BMC Med. 2012 Nov 29;10:150. doi: 10.1186/1741-7015-10-150.


Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial.

Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, Gluud C, Hedetoft C, Jarloev A, Jensen T, Krarup T, Johansen LB, Lund SS, Madsbad S, Mathiesen E, Moelvig J, Nielsen F, Perrild H, Pedersen O, Roeder M, Sneppen SB, Snorgaard O, Tarnow L, Thorsteinsson B, Vaag A, Vestergaard H, Wetterslev J, Wiinberg N; CIMT Trial Group.

Diabetes Obes Metab. 2009 Apr;11(4):315-22. doi: 10.1111/j.1463-1326.2008.00959.x.


Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis.

Burgmann K, Fatio S, Jordi B, Rutishauser J.

Swiss Med Wkly. 2013 Oct 25;143:w13871. doi: 10.4414/smw.2013.13871.


Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.

Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS.

Metabolism. 2011 Oct;60(10):1363-71. doi: 10.1016/j.metabol.2010.09.012. Epub 2010 Nov 16.


Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.

Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN.

Parkinsonism Relat Disord. 2012 Jul;18(6):753-8. doi: 10.1016/j.parkreldis.2012.03.010. Epub 2012 Apr 10.


Smoking as a risk factor for thyroid volume progression and incident goiter in a region with improved iodine supply.

Ittermann T, Schmidt CO, Kramer A, Below H, John U, Thamm M, Wallaschofski H, Völzke H.

Eur J Endocrinol. 2008 Dec;159(6):761-6. doi: 10.1530/EJE-08-0386. Epub 2008 Sep 2.


Poor glycemic control is associated with the risk of subclinical hypothyroidism in patients with type 2 diabetes mellitus.

Cho JH, Kim HJ, Lee JH, Park IR, Moon JS, Yoon JS, Lee IK, Won KC, Lee HW.

Korean J Intern Med. 2016 Jul;31(4):703-11. doi: 10.3904/kjim.2015.198. Epub 2016 Jun 8.


Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.

Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G.

Diabetes Obes Metab. 2013 Jan;15(1):55-61. doi: 10.1111/j.1463-1326.2012.01674.x. Epub 2012 Sep 9.


Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.

Wang MM, Lin S, Chen YM, Shu J, Lu HY, Zhang YJ, Xie RY, Zeng LY, Mu PW.

Diabetes Res Clin Pract. 2015 Jun;108(3):e67-70. doi: 10.1016/j.diabres.2015.02.022. Epub 2015 Mar 13.


Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.

Ekström N, Miftaraj M, Svensson AM, Andersson Sundell K, Cederholm J, Zethelius B, Gudbjörnsdottir S, Eliasson B.

Diabetes Obes Metab. 2012 Aug;14(8):717-26. doi: 10.1111/j.1463-1326.2012.01591.x. Epub 2012 Apr 1.


Diabetes: insulin plus metformin for T2DM--are there benefits?

Bailey CJ.

Nat Rev Endocrinol. 2012 Jun 26;8(8):449-50. doi: 10.1038/nrendo.2012.106. No abstract available.


Supplemental Content

Support Center